107 related articles for article (PubMed ID: 26725706)
1. Rapid and clinically significant response to masitinib in the treatment of mucosal primary esophageal melanoma with somatic KIT exon 11 mutation involving brain metastases: A case report.
Prosvicova J; Lukesova S; Kopecky J; Grim J; Papik Z; Kolarova R; Navratilova B; Dubreuil P; Agopian J; Mansfield C; Moussy A; Hermine O
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Dec; 159(4):695-7. PubMed ID: 26725706
[TBL] [Abstract][Full Text] [Related]
2. Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?
Turner MC; Rossfeld K; Salama AK; Tyler D; Beasley G
Expert Opin Pharmacother; 2017 Apr; 18(5):487-495. PubMed ID: 28277830
[TBL] [Abstract][Full Text] [Related]
3. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
[TBL] [Abstract][Full Text] [Related]
4. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
[TBL] [Abstract][Full Text] [Related]
5. Complete response in a melanoma patient treated with imatinib.
Brown MC; Casasola RJ
J Laryngol Otol; 2012 Jun; 126(6):638-40. PubMed ID: 22643209
[TBL] [Abstract][Full Text] [Related]
6. Masitinib for the treatment of mild to moderate Alzheimer's disease.
Folch J; Petrov D; Ettcheto M; Pedrós I; Abad S; Beas-Zarate C; Lazarowski A; Marin M; Olloquequi J; Auladell C; Camins A
Expert Rev Neurother; 2015 Jun; 15(6):587-96. PubMed ID: 25961655
[TBL] [Abstract][Full Text] [Related]
7. The secondary KIT mutation p.Ala510Val in a cutaneous mast cell tumour carrying the activating mutation p.Asn508Ile confers resistance to masitinib in dogs.
Gentilini F; Turba ME; Dally C; Takanosu M; Kurita S; Bonkobara M
BMC Vet Res; 2020 Feb; 16(1):64. PubMed ID: 32075643
[TBL] [Abstract][Full Text] [Related]
8. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
9. Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma.
Pala L; Conforti F; Cocorocchio E; Ferrucci PF
Anticancer Drugs; 2020 Jul; 31(6):652-654. PubMed ID: 32011367
[TBL] [Abstract][Full Text] [Related]
10. Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
Zukotynski K; Yap JT; Giobbie-Hurder A; Weber J; Gonzalez R; Gajewski TF; O'Day S; Kim K; Hodi FS; Van den Abbeele AD
Cancer Imaging; 2014 Nov; 14(1):30. PubMed ID: 25609545
[TBL] [Abstract][Full Text] [Related]
11. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
Humbert M; de Blay F; Garcia G; Prud'homme A; Leroyer C; Magnan A; Tunon-de-Lara JM; Pison C; Aubier M; Charpin D; Vachier I; Purohit A; Gineste P; Bader T; Moussy A; Hermine O; Chanez P
Allergy; 2009 Aug; 64(8):1194-201. PubMed ID: 19614621
[TBL] [Abstract][Full Text] [Related]
12. Masitinib (AB1010), from canine tumor model to human clinical development: where we are?
Marech I; Patruno R; Zizzo N; Gadaleta C; Introna M; Zito AF; Gadaleta CD; Ranieri G
Crit Rev Oncol Hematol; 2014 Jul; 91(1):98-111. PubMed ID: 24405856
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A; Blay JY; Bui BN; Bouché O; Adenis A; Domont J; Cioffi A; Ray-Coquard I; Lassau N; Bonvalot S; Moussy A; Kinet JP; Hermine O
Eur J Cancer; 2010 May; 46(8):1344-51. PubMed ID: 20211560
[TBL] [Abstract][Full Text] [Related]
14. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
15. A canine case of malignant melanoma carrying a KIT c.1725_1733del mutation treated with toceranib: a case report and in vitro analysis.
Tani H; Miyamoto R; Noguchi S; Kurita S; Nagashima T; Michishita M; Yayoshi N; Tamura K; Bonkobara M
BMC Vet Res; 2021 Apr; 17(1):147. PubMed ID: 33827546
[TBL] [Abstract][Full Text] [Related]
16. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.
Guo J; Si L; Kong Y; Flaherty KT; Xu X; Zhu Y; Corless CL; Li L; Li H; Sheng X; Cui C; Chi Z; Li S; Han M; Mao L; Lin X; Du N; Zhang X; Li J; Wang B; Qin S
J Clin Oncol; 2011 Jul; 29(21):2904-9. PubMed ID: 21690468
[TBL] [Abstract][Full Text] [Related]
17. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
18. Anorectal melanoma with a KIT-activating mutation, which is a target for tyrosine kinase inhibitor.
Itoh M; Goto A; Wakasugi H; Yoshida Y; Matsunaga Y; Fujii K; Suzuki K; Yonezawa K; Abe T; Arimura Y; Shinomura Y
Int J Clin Oncol; 2011 Aug; 16(4):428-34. PubMed ID: 21069551
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of masitinib for treating systemic mastocytosis.
Laforgia M; Marech I; Nardulli P; Calabrò C; Gadaleta CD; Ranieri G
Expert Opin Pharmacother; 2019 Sep; 20(13):1539-1550. PubMed ID: 31381378
[No Abstract] [Full Text] [Related]
20. [A Case of Advanced Malignant Melanoma of the Esophagus with Distant Metastases].
Shida A; Takahashi T; Yanagihara M; Shibuya J; Suzuki K; Kubo Y
Gan To Kagaku Ryoho; 2015 Aug; 42(8):989-91. PubMed ID: 26321715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]